Improving access to highly effective emergency contraception: an assessment of barriers and facilitators to integrating the levonorgestrel IUD as emergency contraception using two applications of the Consolidated Framework for Implementation Research
Implementation Science Communications volume 3, Article number: 129 (2022)
Emergency contraception prevents unwanted pregnancy after sexual intercourse. New evidence has demonstrated that the levonorgestrel 52 mg IUD is a highly effective method of emergency contraception. However, translating this research finding into clinical practice faces existing barriers to IUD access, including costs and provider training, novel barriers of providing IUDs for emergency contraception at unscheduled appointments. The purpose of this study was to identify barriers and facilitators to the utilization of the levonorgestrel IUD as emergency contraception from client, provider, and health systems perspectives.
We conducted English and Spanish-speaking focus groups (n=5) of both contraceptive users (n=22) and providers (n=13) to examine how the levonorgestrel IUD as EC was perceived and understood by these populations and to determine barriers and facilitators of utilization. We used findings from our focus groups to design a high-fidelity in-situ simulation scenario around EC that we pilot tested with clinical teams in three settings (a county health department, a community clinic, and a midwifery clinic), to further explore structural and health systems barriers to care. Simulation scenarios examined health system barriers to the provision of the levonorgestrel IUD as EC. We coded both focus groups and in-clinic simulations using the modified Consolidated Framework for Implementation Research (CFIR). We then applied our findings to the CFIR-Expert Recommendations for Implementing Change (ERIC) Barrier Busting Tool and mapped results to implement recommendations provided by participants.
Ultimately, 9 constructs from the CFIR were consistently identified across focus groups and simulations. Main barriers included suboptimal knowledge and acceptability of the intervention itself, appropriately addressing knowledge and education needs among both providers and contraceptive clients, and adequately accounting for structural barriers inherent in the health system. The CFIR-ERIC Barrier Busting Tool identified eight strategies to improve levonorgestrel IUD as EC access: identifying implementation champions, conducting educational meetings, preparing educational toolkits, involving patients and their partners in implementation, conducting a local needs assessment, distributing educational materials, and obtaining patient feedback.
To sustainably incorporate the levonorgestrel IUD as EC into clinical practice, education, health systems strengthening, and policy changes will be necessary.
Emergency contraception (EC) is a critical tool to reduce unwanted pregnancy after unprotected intercourse. Until recently, there were three options for emergency contraception in the United States: oral levonorgestrel (LNG), oral ulipristal acetate, and the copper IUD. Each of these methods has benefits and limitations in their use (see Table 1).
For example, oral LNG is available over-the-counter, making it the most widely used method of emergency contraception in the United States, but this has also resulted in it not being billable to insurers. With widely variable pricing and the need to pay out-of-pocket, it is often cost-prohibitive to people with lower incomes. Among these commonly used EC methods, oral levonorgestrel is the least effective (pregnancy rates of 1.7–2.6 per single cycle of use) [1,2,3], is less forgiving of use beyond 72 h after unprotected intercourse, and its efficacy is further limited by increasing body weight. A recent study found that doubling the dosage of oral levonorgestrel did not improve rates of unintended pregnancy among people at higher body mass index (BMI) .
Ulipristal acetate is the most effective oral emergency contraceptive (pregnancy rates of 1.2–1.8 per single cycle of use [2, 3, 5]) with a wider dosing window (120 h after unprotected intercourse) and is effective for people at higher BMI, but is only available by prescription. As such, barriers to its timely access (needing to first meet with a healthcare provider and then have a prescription filled at the pharmacy, which often does not stock ulipristal acetate and thus must order it — resulting in increased delays) are much higher, resulting in very low utilization of this method.
The copper intrauterine device (IUD) is the most effective of the available methods at preventing pregnancy (<0.1% of use results in pregnancy) and provides a long-term solution to prevent pregnancy after use . However, among IUDs, the copper IUD is less popular than the LNG IUD because of some of the side effects associated with the copper IUD, such as a heavier bleeding profile [3, 7, 8]. For ongoing contraception, many people prefer the LNG IUD because it reliably reduces or eliminates menstrual bleeding and discomfort [9,10,11]. Despite the preference shown to LNG IUD over the copper IUD, until recently patients have not been able to receive the LNG IUD for emergency contraception, due to a lack of sufficient efficacy data . A recently conducted randomized controlled trial found that the LNG 52 mg IUD (please note all mentions of LNG IUD in this paper refer to the 52mg variety) demonstrates high efficacy for emergency contraception . The participant-blinded randomized noninferiority trial compared outcomes of women seeking an IUD as EC who received either the 52 mg LNG IUD or the copper IUD. One-month pregnancy rates were 0.3% (95% CI: 0.1, 1.7) in the LNG group and 0.0% (95% CI: 0, 1.1) in the copper IUD group, demonstrating that both methods are effective in preventing pregnancy when used as emergency contraception . This efficacy data opens the door for LNG 52 mg IUDs to be the next method option for emergency contraception: the first new method of emergency contraception since ulipristal acetate was FDA-approved for oral emergency contraception in 2010 . Now is a critical time to implement these findings because both emergency contraception and IUD use are steadily increasing, with over one fourth of reproductive age women reporting having used emergency contraception and greater than 1 in 10 contraceptive users selecting IUDs.
If the LNG IUD were broadly available as emergency contraception, it may prove to be the more preferred IUD emergency contraception method and offer additional benefits to people seeking an IUD for their emergency contraception needs. Studies have demonstrated that offering a wider selection of methods increases contraceptive satisfaction and reduces unintended pregnancy . Expanding method choice for emergency contraception will have an extensive clinical impact if these findings can be broadly disseminated and implementation barriers can be identified and addressed early.
To date, dissemination and implementation of best practices surrounding contraceptive research is limited . Successful translation of research typically takes many years and may be stymied by unforeseen or unaddressed barriers to implementation . For example, while IUDs and implants are in high demand, access barriers such as lack of provider training on insertion and removal still impede their wider availability, particularly in primary care settings . Uptake of the LNG IUD as emergency contraception will face some of those same existing barriers, as well as additional challenges to use, such as the need to provide same-day services . Additionally, providers will need to be educated on how to counsel on IUDs as a method of emergency contraception, and patients will need to know that IUDs are an option for EC. To ensure the clinical research regarding the effectiveness of LNG IUDs as EC is translated into practice, the next critical step is to assess possible barriers and facilitators to use of LNG IUDs as EC in a clinical setting.
This study sought to address the issue of successful implementation by collecting and analyzing data on key aspects of patient, provider, and health system barriers and facilitators to implementing the LNG IUD as emergency contraception, as well as identify potential implementation strategies for future interventions. The barriers and facilitators combined with solutions identified in this study should help to develop guidance and recommendations for best practice to implement IUD as emergency contraception as well as health systems strengthening mechanisms to support clinics, providers, and patients facing barriers to emergency contraception access.
To understand the barriers and facilitators to provide LNG IUDs as emergency contraception, we conducted exploratory research in three ways: (1) focus groups with clinical providers who offer contraceptive care in practice, including IUDs; (2) focus groups with community members who have had prior experience with contraceptive care (any method); and (3) in-clinic simulation training including providers and clinical staff. The focus groups allowed us to investigate facilitators and barriers from both the patient and provider perspectives. The simulations allowed us to expand from individual perspectives to health system-level barriers, including organizational and workflow limitations.
We developed semi-structured discussion guides for both provider and community member focus groups. The discussion guides were built around key constructs from the Consolidated Framework for Implementation Research (CFIR) , an implementation tool which was also used to guide our analysis. The provider discussion guide focused on providers’ clinical knowledge of IUDs, their understanding and experience of using IUDs as EC, as well as examining how providers typically receive updated clinical guidance and care recommendations. The community member discussion guide focused on understanding participants’ experiences with IUDs (particularly hormonal IUDs) and capturing their knowledge and beliefs around the use of IUDs as emergency contraception.
Community member participants were recruited from the HER Salt Lake research study, a prospective cohort study that occurred between September 2015 and March 2017. The HER Salt Lake sample consisted of women aged 18–45 years of age receiving new contraceptive services at health centers in Salt Lake County, Utah . We only contacted participants who indicated on prior consents that they were willing to participate in future research, were of reproductive age (between 18-45), were current or prior residents of Utah, and were currently trying to prevent pregnancy. Additionally, we recruited participants through University of Utah-affiliated community Latine/a/o organizations. Participants were consented and included on a first response basis up to 20 participants, per group, to account for scheduling conflicts and unexpected no-show participants during the focus group. English-speaking focus groups were conducted by members of the study team (RS and SE) and the Spanish-speaking focus group was conducted by a local community facilitator fluent in Spanish. All interviewers were female, held higher education credentials, and had prior experience and training in conducting focus groups. Focus groups occurred and were recorded on Zoom. All focus groups took approximately 60 min.
Healthcare providers were recruited by contacting community clinicians participating in Family Planning Elevated, a Utah statewide contraceptive initiative , as well as University of Utah faculty listservs to women’s health care departments. Providers were eligible to participate if they were currently employed as a healthcare clinician and currently offering contraceptive care as part of their healthcare practice. All provider types (e.g., physician, physician’s assistant, nurse practitioner) meeting these criteria were considered eligible for these focus groups. Focus groups occurred and were recorded on Zoom. All focus groups took approximately 60 min.
Once a potential participant expressed interest, an enrollment email was sent with the full consent language both as an attachment and in the body text of the email. Participants were enrolled and included in the focus group if they responded affirmatively to the consent communication. Participants received gift card compensation for their time. All focus groups were audio recorded and transcribed verbatim. The Spanish-speaking focus group audio was translated by the University of Utah language translators, who provide all professional health language translation for the university.
The LIFT Simulation Design Lab, at the University of Utah, designed a 2-h emergency contraception clinical training. Simulation was selected as an appropriate method to gain insight within a clinical setting as there is a significant body of evidence from varied clinical settings that demonstrates the value of incorporating highly realistic simulation techniques into in-service training for improving clinical decision-making, teamwork, and use of evidence-based practices [21,22,23,24]. Simulation can both identify barriers and facilitators of health systems implementation, and provide opportunities for technical education and improvement to team communication [25,26,27,28]. The simulation training was designed with the following components: (1) brief didactic training sharing the current evidence around the efficacy of the LNG 52 mg IUD as EC, as well as a review of currently offered methods of EC; (2) simulations scenario(s) with facilitated debrief; and (3) discussion of barriers/facilitators to EC access in the clinical setting (see Fig. 1).
The simulation training was pilot tested within the University of Utah’s Family Planning Division team prior to clinic recruitment. We recruited clinics via email, inviting them to participate in a 2-h in-clinic simulation training on the use of LNG IUDs as EC. Clinics recruited included those which had participated in Family Planning Elevated and clinics which had expressed prior interest in engaging around contraceptive training. Clinics were eligible to participate if IUDs were offered as a contraceptive method at the time of the simulation. Participants were consented prior to participation by emailing the consent document to participating staff. Prior to initiating the training, the consent was reviewed, and assent confirmed. Participating clinics did not receive financial compensation for participation.
The trainings were conducted collaboratively by the University of Utah Family Planning team and LIFT Lab simulation team members. Each of these individuals is female, possesses higher education credentials, and has had prior experience and training in conducting simulations in clinical settings. One member of the Family Planning team (JB) collected field notes during the training. The field notes included a list of barriers the clinic teams identified during the training, as well as any solutions they identified to those barriers. Following each training, those barriers and solutions were organized into memos containing key points, barriers, and solutions from each training.
The study follows the COnsolidated criteria for REporting Qualitative research (COREQ) guidelines for qualitative research (see Fig. 1). All focus group audio recordings were transcribed, verbatim, and the Spanish focus group was translated into English. Transcripts were uploaded to Dedoose Version 8.0.35 . The research team conducted a content analysis of the data, using an adapted the CFIR codebook  for use in this study. CFIR supports rapid-cycle evaluation of the implementation of complex health care delivery interventions due to its comprehensive framework for identifying factors that may emerge in various, multi-level contexts that subsequently influence implementation. The initial codebook included 39 codes. The team collaboratively (RS, JB, SE) coded one provider focus group and one community member focus group, and further refined the CFIR codebook based on which codes emerged as salient, and which did not, until saturation occurred. The revised codebook contained 18 CFIR constructs. Final transcript coding was conducted by individual team members (JB, SE) using the refined codebook. Codes and representative quotes were organized into a CFIR matrix, following the principles of Framework Analysis . Finally, field notes detailing clinic-level barriers from each of the simulation trainings were also mapped onto the CFIR matrix, with solutions categorized separately.
After completing coding and mapping onto the framework, we subsequently ran our findings through the CFIR-ERIC Barrier-Buster tool (V0.53) which was developed to match CFIR constructs to corresponding Expert Recommendations for Implementing Change (ERIC) strategies . The top eight endorsed ERIC implementation strategies were compared and mapped along with proposed solutions provided by participants. We utilized the refined compilation of implementation strategies  to provide further clarifying language around recommended approaches.
Twenty-two individuals participated in the three client focus groups (6 in the Spanish-speaking group; 16 in the two English-speaking groups). The two provider focus groups consisted of 13 participants: four medical doctors, four certified nurse-midwives, four nurse practitioners, and one physician assistant. Seven providers are employed within the University of Utah and six are employed in community clinics within the state of Utah. All participants currently provide contraceptive care in the state of Utah.
Four clinics received the emergency contraception simulation training: one county health department, two community clinics, and one midwifery practice. Participating clinic staff included nurse practitioners, registered nurses, physician assistants, medical assistants, clinic managers, front desk managers, and nursing students.
Table 2 provides an overview of CFIR constructs identified through focus groups and simulations, with descriptive quotations for each construct. Of the original eighteen constructs in our revised CFIR codebook, nine constructs were used most frequently across the groups. We combined “Structural Characteristics” and “Complexity” into one construct, as they had considerable overlap in our results and have sufficient conceptual overlap as constructs to warrant combining. Structural characteristics describe the setting in which the intervention is implemented, and compatibility describes the degree of fit between the intervention and implementation site.
Evidence strength and quality
LNG 52 mg IUDs are not currently FDA-approved as a method of emergency contraception [33, 34]. Some providers participating in the simulations noted that this created some concern around counseling for this use. Providers also would like to see organizations, such as the American College of Obstetrics and Gynecology, adopt formal recommendations for its use as EC. For clients, the focus was on how to interpret the evidence around the effectiveness of the IUD as emergency contraception. Many clients felt that the effectiveness of IUDs as EC should be presented alongside information about the effectiveness of the IUD as a method of contraception, since a person may need both pieces of information to make an informed choice.
Providers identified several challenges to offering LNG IUD as EC, including the availability of same-day services for insertion. To insert an IUD, the provider typically conducts pregnancy testing. The tests, plus the time needed for counseling and device insertion, often make IUD appointments longer than other contraceptive visits. Providers struggled with the desire to make the LNG IUD as EC available, while also accounting for current low demand for their use as EC and the need for scheduling flexibility to ensure same-day availability. The challenges of LNG IUD as EC largely mirrored existing challenges of providing copper IUD as EC. For clients, there was decisional complexity around the use of the IUD as EC. Aspects such as pain at insertion and the long-term commitment of the method were juxtaposed against the method’s high efficacy at preventing pregnancy. The simulation also identified that counseling around potential contraindications for an IUD could also increase the complexity of offering the LNG IUD as EC.
Patient needs and resources
Providers noted challenges some subpopulations may face in accessing the LNG IUD in an emergency setting. Clients in carceral settings, clients experiencing homelessness, and clients with challenges accessing broader healthcare (e.g., transportation challenges and lack of health insurance coverage) would likely not find this method widely accessible. In-clinic simulations underscored the challenges for clients who were un- or under-insured. Clients also noted that there could be two distinct groups of individuals choosing the LNG IUD as EC. The first group identified would select the LNG IUD because the method was highly effective as EC and the second would choose the LNG IUD as EC because they both needed EC and an ongoing method. For those who simply needed the LNG IUD as EC, the issue of how to remove it after the immediate threat of pregnancy had passed was an important consideration, particularly given the high cost of both insertion and removal procedures.
Providers also shared significant concerns about their ability to offer the LNG IUD as EC to adolescents, who they noted are major utilizers of emergency contraception. Providers felt that adolescents, particularly nulliparous adolescents, are more likely to experience high pain levels at insertion and insertion is more likely to be considered difficult.
Clients also discussed cultural considerations around Utah’s largely religious population, noting that partner involvement in contraceptive decision-making may look different when the emergency method ends up being a long-term method.
External policy and incentives
In 1983, Utah passed a law preventing clinics receiving state funding from providing care to teens without parental consent. Though this law was ultimately overruled in a court challenge (Planned Parenthood Association of Utah v. Matheson, 1983), its continued existence on the books causes confusion and concern among providers. Providers brought up concerns about their ability to provide care to adolescents in need of EC without parental consent, despite the law being unenforceable. For clients, the over-the-counter availability of oral emergency contraception was seen as an easier option than the process required to obtain an IUD for a similar purpose.
Structural characteristics and compatibility
Simulation trainings demonstrated many challenges to providing IUD as EC services, including the lack of same-day appointments, the availability of clinical staff to support an insertion without a prior appointment, clinic competing priorities for same-day walk-in services (such as COVID vaccines), and stocking challenges of IUDs, which are expensive to purchase without guaranteed use. Providers also noted that scheduling within the required 5-day window for services, particularly if some of those days occur over the weekend, would be a challenge. Similarly, clients noted the difficulty of getting an appointment when desired, given how full most clinics are, a difficulty especially prevalent in low-income clinics. The cost of the IUD was also a main barrier for clients, particularly if it was not fully covered by insurance and the intended use was for a short period of time. This is true for both the copper and LNG IUDs, which can cost more than $1000 if the patient is paying out-of-pocket.
Access to knowledge and information
Both providers and clients were unfamiliar with the use of an IUD for EC and demonstrated confusion over the mechanism of action of the LNG IUD as an emergency contraceptive. Clients noted, more broadly, that they were unaware of most other emergency contraceptive options outside of the oral LNG emergency contraceptive (e.g., ulipristal acetate or the copper IUD). Providers who were affiliated with research institutions were more likely to have access to current evidence, such as the effectiveness of LNG IUDs as emergency contraception.
Characteristics of individuals
Knowledge and beliefs about the intervention
A barrier identified during both client and provider focus groups, as well as during simulation training, was a lack of awareness of EC options beyond oral LNG (Plan B). Clients shared that even when they were aware of all their options, they were often confused about where and how to access each of the methods. Providers and clients also lacked understanding about the mechanisms of action for each of the EC methods. Specifically, providers were uncertain about how IUDs work for EC, with some incorrectly believing that IUDs can act as an abortifacient to an established pregnancy, and others unsure if it is appropriate to place an IUD when an individual is at risk of being pregnant but has a negative urine pregnancy test (current evidence [35,36,37] indicates it is appropriate).
When discussing the use of IUDs (for EC or as ongoing contraception) some providers described IUDs as a method of birth control that is “best” or “right” for their patients. While providers acknowledged that it is ultimately up to the patient to select the method that is best for them, many spoke of the need to persuade patients that the process of inserting IUDs isn’t as bad as they may imagine. The view some providers had of IUDs as a universal good stood in stark contrast to experiences shared by some patients. Some patients described the IUD insertion as very painful. Many of those who experienced pain during the insertion wished their providers had been more forthcoming about how painful the insertion could be, and shared recommendations for managing the pain during and following the procedure.
The CFIR-ERIC Barrier Buster tool identified seven “Level 1” strategies (i.e., where a majority of implementation experts agreed the approach was in their top seven strategies to address a particular CFIR barrier) across four of the nine CFIR constructs identified in our analyses (see Table 3). The seven strategies were (1) identify and prepare champions, (2) conduct educational meetings, (3) develop educational materials, (4) involve patients, (5) conduct local needs assessment, (6) distribute educational materials, and (7) obtain and use patient feedback. A focused implementation package involving these seven strategies should be tested for feasibility and scalability within clinical settings.
Additional strategies identified by study participants included the development and strengthening both the educational and referral pathways between the pharmacy and clinical care settings, to ensure clients seeking oral EC from a pharmacy were aware of (a) the limitations of oral EC among individuals with higher body mass index (and thus, these individuals may benefit from an IUD as EC, which does not have weight limitations) and (b) that the IUD as EC has higher efficacy for all people, and thus may be an important avenue for people with very high prioritization on not becoming pregnant.
Participants also noted the importance of changing clinical care pathways so that standard contraceptive visits include counseling about and possible provision of EC. Counseling about the LNG IUD as EC during a normal contraceptive visit should also include information about the possibility to have it removed after the immediate threat of pregnancy has passed. Recommendations to ensure provision of LNG IUD as EC was possible in standard clinical settings included the importance of educating the entire medical team (e.g., front desk staff, medical assistants, providers) on how to ensure clients seeking these services could get same-day care, as well as obtaining support from administrative staff on creating openings to provide these services to drop-in clients.
This study assessed potential barriers and facilitators to utilization of the LNG IUD as EC with the aim to develop an implementation intervention. Use of the LNG IUD as EC has many potential benefits to patients. IUDs (both the LNG and copper) are an important option for patients who need highly effective EC, those with higher body mass index for whom oral EC may be less effective , and for patients who desire ongoing contraceptive methods. To realize these benefits to patients, interventions aimed at improving accessibility of IUDs as EC will need to address underlying challenges to its implementation. Findings in the CFIR framework demonstrated barriers at the external, internal, and intervention levels, which would require strategies at multiple levels of the health system, including governance, clinical, provider, and patient levels in order to successfully address challenges.
Notably, many barriers identified in our study have also been identified in studies on other methods of emergency contraception . Studies on barriers to use of both ulipristal acetate, a prescription-only oral emergency contraceptive, and the copper IUD as EC, have found issues of knowledge/awareness, cost, and healthcare system barriers to be key components of low utilization [40,41,42]. Many studies of EC have noted the misperception that these methods result in abortion [39, 43, 44]. Thus, many of the strategies to improve uptake of the LNG IUD as EC are likely also needed to improve uptake of any EC method and it is possible that successful interventions could target improving access to EC broadly, rather than simply focusing on LNG IUD as EC. However, some strategies are specific only to the LNG IUD, such as distributing specific evidence around the use of LNG IUD as EC, seeking FDA approval for its use as an EC, and receiving recommendations for its use as EC from organizations that produce clinical guidelines such as ACOG, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO).
Similarly, many of the barriers to use of IUDs as EC are similar to known barriers to IUD use broadly. Cost of intrauterine devices is often prohibitive for patients  and the burden of these costs may be further perceived as too high if the device is only used for a short period of time. Addressing IUD insertion pain has been an ongoing challenge for implementors interested in increasing access to these devices . Further, addressing provider bias toward these methods is also a general challenge around intrauterine device use and promotion . Use of the IUD in emergency scenarios likely compounds, rather than diminishes these challenges.
This study sought multiple perspectives in order to fully identify implementation challenges to offering the LNG IUD as EC in clinical settings. Mapping both the CFIR framework and the CFIR-ERIC Barrier tool to participant responses was an effective approach to contextualizing implementation challenges and potential solutions in an intervention planning phase. Potential limitations to our study include the generalizability of our sample, given that all participants live/practice in Utah. As each state and country has different external environments, our findings may not represent the full context or impact of various state/country policies on EC provision and coverage. Intervention designs require local context, as well as expert recommendations, in order to be successful, but individuals interested in implementing this intervention elsewhere could likely map their work onto our findings as a starting point.
Availability of the levonorgestrel IUD as a new form of EC has potential to benefit many people seeking to prevent pregnancy after unprotected sex who also desire an ongoing method of contraception with a favorable benefit profile. To successfully provide access to this method, implementing teams must support development of robust referral pathways among pharmacy and clinical settings, ensure patients and providers are aware of IUDs as an option for EC, and work with healthcare teams to incorporate IUDs as EC into clinic workflow and standard practice.
Availability of data and materials
The qualitative data supporting the conclusions of this article is available upon request.
Consolidated Framework for Implementation Research
Expert Recommendations for Implementing Change
Food and Drug Administration
von Hertzen H, Piaggio G, Ding J, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002;360(9348):1803–10. https://doi.org/10.1016/s0140-6736(02)11767-3.
Creinin MD, Schlaff W, Archer DF, et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet Gynecol. 2006;108(5):1089–97. https://doi.org/10.1097/01.Aog.0000239440.02284.45.
Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010;375(9714):555–62. https://doi.org/10.1016/s0140-6736(10)60101-8.
Edelman AB, Hennebold JD, Bond K, et al. Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled Trial. Obstet Gynecol. 2022;10:1097.
Li HW, Lo SS, Ng EH, Ho PC. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. Hum Reprod. 2016;31(6):1200–7. https://doi.org/10.1093/humrep/dew055.
Goldstuck ND, Cheung TS. The efficacy of intrauterine devices for emergency contraception and beyond: a systematic review update. Int J Womens Health. 2019;11:471.
Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod. 2012;27(7):1994–2000.
Von Hertzen H, Piaggio G, Peregoudov A, et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002;360(9348):1803–10.
Diedrich JT, Desai S, Zhao Q, Secura G, Madden T, Peipert JF. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1):50. e1–8.
Sanders JN, Myers K, Gawron LM, Simmons RG, Turok DK. Contraceptive method use during the community-wide HER Salt Lake Contraceptive Initiative. Am J Public Health. 2018;108(4):550–6.
Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol. 2011;117(5):1105.
Turok DK, Sanders JN, Thompson IS, Royer PA, Eggebroten J, Gawron LM. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study. Contraception. 2016;93(6):526–32.
Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021;384(4):335–44.
Gavin L, Moskosky S, Carter M, et al. Providing quality family planning services: recommendations of CDC and the US Office of Population Affairs. Morb Mortal Wkly Rep Recomm Rep. 2014;63(4):1–54.
Wensing M, Grol R. Knowledge translation in health: how implementation science could contribute more. BMC Med. 2019;17(1):88.
Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med. 2011;104(12):510–20.
Baron M, Potter B, Schrager S. A review of long-acting reversible contraception methods and barriers to their use. WMJ. 2018;117(4):156–9.
Biggs MA, Harper CC, Brindis CD. California family planning health care providers' challenges to same-day long-acting reversible contraception provision. Obstet Gynecol. 2015;126(2):338–45.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementat Sci. 2009;4(1):1–15.
Simmons RG, Myers K, Gero A, et al. Evaluating a Longitudinal Cohort of Clinics Engaging in the Family Planning Elevated Contraceptive Access Program: Study Protocol for a Comparative Interrupted Time Series Analysis. JMIR Res Protocols. 2020;9(10):e18308.
Yucel C, Hawley G, Terzioglu F, Bogossian F. The effectiveness of simulation-based team training in obstetrics emergencies for improving technical skills: a systematic review. Simul Healthc. 2020;15(2):98–105.
Sandeva MG, Tufkova S, Ketev K, Paskaleva D. Evaluating the Effectiveness of Simulation Training in Obstetrics and Gynecology, Pediatrics and Emergency Medicine. Folia Med. 2019;61:605.
Seam N, Lee AJ, Vennero M, Emlet L. Simulation training in the ICU. Chest. 2019;156(6):1223–33.
Saadi A, Uddin T, Fisher M, Cross S, Attoe C. Improving Interprofessional Attitudes Towards Mental and Physical Comorbidities: The Effectiveness of High Fidelity Simulation Training Versus Roleplay. Clin Simul Nurs. 2021;54:22–9.
Brogaard L, Glerup Lauridsen K, Løfgren B, et al. The effects of obstetric emergency team training on patient outcome: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2022;101(1):25–36.
Aljahany M, Alassaf W, Alibrahim AA, et al. Use of in situ simulation to improve emergency department readiness for the COVID-19 pandemic. Prehosp Disaster Med. 2021;36(1):6–13.
Walker D, Cohen S, Fritz J, et al. Team training in obstetric and neonatal emergencies using highly realistic simulation in Mexico: impact on process indicators. BMC Pregnancy Childbirth. 2014;14(1):1–11.
Saraswathy T, Nalliah S, Rosliza A, et al. Applying interprofessional simulation to improve knowledge, attitude and practice in hospital-acquired infection control among health professionals. BMC Med Educ. 2021;21(1):1–11.
Dedoose. Version Version 8.0.35. SocioCultural Research Consultants 2018. www.dedoose.com
Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13(1):1–8.
Waltz TJ, Powell BJ, Fernández ME, Abadie B, Damschroder LJ. Choosing implementation strategies to address contextual barriers: diversity in recommendations and future directions. Implement Sci. 2019;14(1):1–15.
Powell BJ, Waltz TJ, Chinman MJ, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. Implement Sci. 2015;10(1):1–14.
Bayer HealthCare Pharmaceuticals Inc. Mirena Package Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021225s027lbl.pdf. Accessed 15 May 2022.
Actavis and Medicines360. LILETTA Package Insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206229s000lbl.pdf. Accessed 15 May 2022.
BakenRa A, Gero A, Sanders J, Simmons R, Fay K, Turok DK. Pregnancy Risk by Frequency and Timing of Unprotected Intercourse Before Intrauterine Device Placement for Emergency Contraception. Obstet Gynecol. 2021;138(1):79.
Thompson I, Sanders JN, Schwarz EB, Boraas C, Turok DK. Copper intrauterine device placement 6–14 days after unprotected sex. Contraception. 2019;100(3):219–21.
Boraas CM, Sanders JN, Schwarz EB, Thompson I, Turok DK. Risk of Pregnancy With Levonorgestrel-Releasing Intrauterine System Placement 6–14 Days After Unprotected Sexual Intercourse. Obstet Gynecol. 2021;137(4):623–5.
Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011;84(4):363–7. https://doi.org/10.1016/j.contraception.2011.02.009.
Group EC, Group ECW, Baird D, et al. Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review. Hum Reprod. 2015;30(4):751–60.
Chan MC, Munro S, Schummers L, et al. Dispensing and practice use patterns, facilitators and barriers for uptake of ulipristal acetate emergency contraception in British Columbia: a mixed-methods study. Can Med Assoc Open Access J. 2021;9(4):E1097–104.
Harper CC, Speidel JJ, Drey EA, Trussell J, Blum M, Darney PD. Copper intrauterine device for emergency contraception: clinical practice among contraceptive providers. Obstet Gynecol. 2012;119(2 Pt 1):220.
Kaller S, Mays A, Freedman L, Harper CC, Biggs MA. Exploring young women’s reasons for adopting intrauterine or oral emergency contraception in the United States: a qualitative study. BMC Womens Health. 2020;20(1):1–9.
Dixit A, Khan M, Bhatnagar I. Mainstreaming of emergency contraception pill in India: Challenges and opportunities. Indian J Community Med. 2015;40(1):49.
Whelan AM, Langille DB, White SJ, Asbridge M, Flowerdew G. Knowledge of, beliefs about, and perceived barriers to the use of the emergency contraception pill among women aged 18-51 in Nova Scotia. Pharm Pract. 2011;9(3):148.
Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Preventing unintended pregnancy: the contraceptive CHOICE project in review. J Womens Health. 2015;24(5):349–53.
Gemzell-Danielsson K, Jensen JT, Monteiro I, et al. Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: An updated review. Acta Obstet Gynecol Scand. 2019;98(12):1500–13.
Higgins JA, Kramer RD, Ryder KM. Provider bias in long-acting reversible contraception (LARC) promotion and removal: perceptions of young adult women. Am J Public Health. 2016;106(11):1932–7.
The authors would like to thank Gabriela Garcia for her expertise in facilitating the simulation portion of this study. We would also like to thank the providers, community members, and clinic teams who kindly shared their time and their perspectives during the study.
The research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number(s) UL1TR002538. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This publication was made possible in part through support from the Utah ASCENT Center for Sexual and Reproductive Health, Policy and Research.
Ethics approval and consent to participate
This study was approved by the University of Utah Institutional Review Board (IRB # 00137804).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Simmons, R.G., Baayd, J., Elliott, S. et al. Improving access to highly effective emergency contraception: an assessment of barriers and facilitators to integrating the levonorgestrel IUD as emergency contraception using two applications of the Consolidated Framework for Implementation Research. Implement Sci Commun 3, 129 (2022). https://doi.org/10.1186/s43058-022-00377-0
- Emergency contraception
- LNG IUD
- Intrauterine device